Researchers have discovered a new way in which RAS genes, which are commonly mutated in cancer, may drive tumor growth beyond their well-known role in signaling at the cell surface. Mutant RAS, they ...

Researchers at the National Institutes of Health (NIH) and their collaborators have discovered a new way in which RAS genes, which are commonly mutated in cancer, may drive tumor growth beyond their ...

Researchers at the National Institutes of Health (NIH) and their collaborators have discovered a new way in which RAS genes, which are commonly mutated in cancer, may drive tumor growth beyond their ...

Researchers at the National Institutes of Health (NIH) and their collaborators have discovered a new way in which RAS genes, which are commonly mutated in cancer, may drive tumor growth beyond their ...

Proteins that are commonly mutated and overexpressed in cancers are called oncoproteins and are typical targets for cancer therapies. Cancer treatment faces significant challenges due to the presence ...

Researchers at the Francis Crick Institute and Vividion Therapeutics have identified chemical compounds that can precisely block the interaction between the major cancer-driving gene RAS, and a key ...

Two original papers in Nature highlight the discovery and translational implications of RMC-7977, a RAS(ON) multi-selective tri-complex inhibitor that exhibits unprecedented anti-tumor activity in ...

Moffitt Cancer Center researchers report the first clinical activity of a RAS inhibitor in patients with NRAS-mutant melanoma. The investigational drug daraxonrasib (RMC-6236) and its preclinical ...

A blue protein ribbon structure labeled PI3Kα has a space-filling molecule bound to it, which interacts (clashes) with a second protein ribbon molecule labeled KRas. This model shows how BBO-10203 ...

Testing older potential organ donors for dangerous "zombie" cells could help to increase the number of hearts available for transplant, according to research presented at the British Cardiovascular ...